Last updated: May 30, 2026
Piqray (alpelisib) Suppliers: Who Makes the API, Key Intermediates, and Finished Dosage Forms
Piqray (alpelisib) is an oncology product marketed in the US by Novartis. The supplier network includes (1) API and intermediate manufacturers that support alpelisib synthesis and (2) contract manufacturing organizations (CMOs) that produce tablets and associated packaging for commercial supply.
No complete, consolidated public dataset exists that cleanly enumerates every upstream and downstream supplier for all geographies and dosage strengths. This response compiles supplier roles that are identifiable from regulatory filings and public manufacturing references tied to alpelisib production and commercial supply chains.
What suppliers manufacture the Piqray (alpelisib) API and intermediates?
API and intermediate manufacturing roles
For small-molecule kinase inhibitors like alpelisib, supply chains typically separate into:
- API manufacturers producing alpelisib drug substance.
- Intermediate manufacturers producing key cyclization, chiral/purification, and functional-group building blocks used in the final API route.
- Specialty process vendors supplying critical reagents and solvents for GMP-scale synthesis.
Publicly traceable supplier identification
In practice, the most reliable supplier visibility for Piqray comes from:
- FDA drug application CMC sections referenced in publicly available summaries (where the manufacturer names are disclosed).
- Inspection/establishment data that points to manufacturing sites for solid oral dose products.
- Regulatory and quality documentation embedded in public records tied to commercial manufacturing sites.
For Piqray specifically, public disclosures allow identification of the finished dosage manufacturing sites more consistently than upstream API/intermediate suppliers.
Which companies supply Piqray tablets and finished dosage forms?
Finished dose manufacturing sites
Piqray is a solid oral tablet product. Finished dosage supply is handled by:
- CMOs performing tablet compression, coating, and packaging under GMP
- Packaging/labeling suppliers for multi-country distribution
How to confirm manufacturing responsibility in practice
Company-level supplier assignment for finished product is typically confirmed by:
- US FDA establishment listings (drug product manufacturing and packaging sites)
- Submission materials that list drug product manufacturer(s) and packager(s) tied to each marketed strength
This is the highest-yield path for supplier due diligence because it ties directly to the manufacturing establishment producing commercial product.
What is the Orange Book status of Piqray and what does it imply for supplier readiness?
Orange Book status and supplier leverage
When a brand faces active generic scrutiny and manufacturing process changes, brand supply stability depends on:
- GMP supply of API that matches the approved commercial process
- Validated control strategy for tablets
- Change control readiness for process scale changes
Piqray’s branded exclusivity and subsequent generic entry activity (where applicable) impact how readily alternative suppliers can qualify API and dosage under comparable specs.
Do generic or biosimilar entrants affect Piqray supplier choices?
Small molecule generics versus supplier reshoring
Piqray’s active ingredient is a small molecule (not a biologic), so:
- Biosimilar dynamics do not apply
- Generic applicants seek API supply and formulation manufacturing pathways that are acceptable for ANDA submission
When generic launches approach, brands may tighten:
- API qualification
- CMO capacity contracts
- release testing capacity to avoid supply disruptions
How many Piqray suppliers exist globally for commercial supply?
Supplier count is geography-dependent
Global oncology supply networks for tablets typically involve:
- One primary drug substance route with backup capability at one or more sites
- One or two tablet/tablet packaging sites per region
However, the number of named suppliers varies by:
- Market (US vs EU vs other)
- Strength-specific packaging formats
- Contract renewals and CMO rebalancing
Because Piqray supplier identity is not published as a single official list covering all roles and countries, supplier counts should be treated as range estimates derived from manufacturing establishment data rather than a single “master vendor list.”
What delivery strengths and packaging formats drive supplier scope for Piqray?
Strength-specific operational scope
Piqray tablets are supplied in multiple strengths, which drives:
- Tablet manufacturing settings (compression forces)
- Coating parameters
- Packaging configuration (bottle vs blister depending on region)
Supplier capability is validated by the ability to meet:
- Tablet uniformity and dissolution specs
- Stability profiles
- Shipping and handling requirements
What manufacturing/IP barriers limit new suppliers for alpelisib?
Key barriers
New suppliers face constraints common to high-potency oral oncology APIs:
- Proven GMP for potent oncology compounds
- Ability to execute validated synthetic steps and impurity control
- Analytical method capability for alpelisib and specified impurities
- Controlled substances and safe-handling infrastructure (where applicable)
Where IP matters
IP can affect:
- Route design (whether alternative synthesis is “freedom to operate”)
- Impurity profile control (matching approved commercial specs)
- Process improvement timelines (avoid creating non-comparable product)
How does Piqray supply compare with other PI3K inhibitors on supplier structure?
Benchmarks
Across PI3K inhibitor small molecules, supply chains often show:
- Concentrated API capacity
- Fewer CMO tablet sites versus broader formulation capacity for less potent small molecules
Piqray is more likely to exhibit constrained manufacturing options due to potency and analytical requirements.
What patent estate issues affect supplier qualification and commercial continuity?
Supplier qualification is affected indirectly by patent timelines
Even when CMC changes are feasible, suppliers must align with:
- Patent-protected commercial manufacturing routes
- Approved process parameters and control strategy
- Validated dissolution and stability to match labeled product
This can slow supplier switching during exclusivity or active litigation.
Key Takeaways
- Piqray (alpelisib) supply involves API and intermediate manufacturing upstream and tablet and packaging CMOs downstream, with finished-dose supplier identification typically more visible than API supplier identity.
- Supplier due diligence for Piqray is most reliably performed through FDA establishment/manufacturing site data and CMC-linked regulatory records tied to commercial supply.
- New API or finished-dose suppliers face operational barriers tied to GMP potency handling, impurity analytics, and process validation, plus indirect constraints from the brand’s patent-protected commercial context.
FAQs
1) Who is the marketing authorization holder for Piqray in the US?
Novartis.
2) Are there biosimilars of Piqray (alpelisib)?
No. Piqray is a small-molecule drug, so the biologics pathway does not apply.
3) What is the most reliable way to identify Piqray drug product manufacturing suppliers?
US FDA drug establishment/manufacturing and packaging site records tied to commercial product.
4) Can alternative API suppliers enter alpelisib supply without regulatory re-qualification?
They must qualify to GMP and analytical/control requirements consistent with an approved product dossier and commercial specs.
5) Do packaging formats change supplier requirements for Piqray?
Yes. Tablet strength and packaging format drive different operational and labeling/packaging line requirements.
References (APA)
- FDA. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
- FDA. (n.d.). Drugs@FDA. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
- FDA. (n.d.). NDC Directory. U.S. Food and Drug Administration. https://www.fda.gov/drugs/drug-approvals-and-databases/national-drug-code-directory
